KYMR Stock Falls -14% With A 7-day Losing Spree On Significant Insider Selling
Kymera Therapeutics (KYMR) stock hit day 7-day losing streak, with cumulative losses over this period amounting to a -14%. The company market cap has crashed by about $1.6 Bil over the last 7 days, and currently stands at $5.8 Bil.
The stock has YTD (year-to-date) return of 6.5% compared to 0.2% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity, or a trap.
What Triggered The Slide?
[1] Substantial Insider Stock Sales
- Microsoft Stock: Is The 15% Drop A Buying Opportunity Or A Warning Sign?
- Adobe Stock Sell-Off: What Happened And Does It Matter?
- What’s Happening With Block Stock?
- When Oil Moves, Bitcoin Bleeds
- This Strategy Pays You 12% While Lining Up PYPL at Bargain Prices
- The Next Big Rally in Microsoft Stock Could Start Like This
- Director Bruce Booth sold 229,809 shares on Dec 10
- ~518,585 shares sold by insiders in the last three months
- Impact: Increased Investor Concern, Sustained Selling Pressure
[2] Technical Reversal From Overbought Conditions
- Sell signal issued from a pivot top point on Dec 8
- Stock considered in ‘overbought territory’ in early December
- Impact: Profit-Taking After Sharp Rally, Negative Momentum
Opportunity or Trap?
Below is our take on valuation.
There are several things to fear in KYMR stock given its overall Weak operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Very Unattractive (For details, see Buy or Sell KYMR).
But here is the real interesting point.
You are reading about this -14% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for KYMR stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | KYMR | S&P 500 |
|---|---|---|
| 1D | -6.5% | 0.2% |
| 7D (Current Streak) | -13.7% | -0.3% |
| 1M (21D) | 13.2% | 0.4% |
| 3M (63D) | 29.9% | 2.1% |
| YTD 2026 | -6.5% | 0.2% |
| 2025 | 93.4% | 16.4% |
| 2024 | 58.0% | 23.3% |
| 2023 | 2.0% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: KYMR Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 7 S&P constituents with 3 days or more of consecutive gains and 111 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 2 | 49 |
| 4D | 2 | 30 |
| 5D | 1 | 24 |
| 6D | 2 | 2 |
| 7D or more | 0 | 6 |
| Total >=3 D | 7 | 111 |
Key Financials for Kymera Therapeutics (KYMR)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $78.6 Mil | $47.1 Mil |
| Operating Income | $-165.5 Mil | $-256.7 Mil |
| Net Income | $-147.0 Mil | $-223.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $11.5 Mil | $2.8 Mil |
| Operating Income | $-84.6 Mil | $-88.7 Mil |
| Net Income | $-76.6 Mil | $-82.2 Mil |
The losing streak KYMR stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.